Cancer

GE Launches MyBreastAI Suite, an AI-Powered Platform for Mammography

GE HealthCare has announced the release of MyBreastAI Suite, a new AI-powered platform for mammography, designed to aid clinicians in detecting breast cancer. This platform integrates AI applications from iCAD, focusing on breast density assessment and enhancing the efficiency of mammography workflows. Addressing the challenges posed by the global rise in breast cancer cases, MyBreastAI Suite aims to streamline breast cancer detection.…

Endometrial Cancer Diagnostics Company MiMARK Secures €4.22M in Seed Funding

MiMARK Diagnostics, a company specializing in women’s health, has completed its first seed funding round, raising €4.22M. The funds are intended to advance their work in gynecological diagnostics, focusing on the use of gynecological fluids as a non-invasive source for biomarker detection. The company received €1.5M from EIT Health back in 2021. MiMARK is developing in vitro diagnostic solutions for managing gynecological…

Kheiron’s AI Tool Mia Increases Breast Cancer Detection Rate by 13%, Nature Study Reveals

UK-based cancertech company Kheiron has made a significant leap in the fight against breast cancer with their AI tool, Mia, as evidenced by a recent study published in Nature Medicine. According to the new paper Mia has demonstrated the ability to increase breast cancer detection by up to 13%. This advancement could potentially reduce the rate of missed cancers by half, translating…

South Korean Breast Cancer Diagnostics Company Lunit Secures $150M to Accelerate Growth

AI-enabled cancer diagnostics company Lunit, recently announced a financial boost with a $150M investment from its shareholders. The South Korean company, listed on the KOSDAQ, plans to invest these funds into new product development and strengthen its foothold in Western markets. The recent funding milestone is complemented by Lunit’s achievement in securing its third 510(k) clearance from the U.S. Food and Drug…

Mammogen Achieves CLIA Validation for Its Early Detection Blood Test for Stage I Diagnosis of Breast Cancer

Mammogen, a precision diagnostics company, has recently completed the Clinical Laboratory Improvement Amendments (CLIA) validation for its genTRU-breast assay. This blood test is designed for the early detection of breast cancer and marks a significant step in the field of women’s health diagnostics. The foundation of Mammogen was inspired by a personal experience: the founder’s sister’s best friend, Katy, was diagnosed with…

Novel Test Offers Alternative to Invasive Womb Cancer Procedures

A recent study funded by The Eve Appeal and published in The Lancet Oncology has introduced a new diagnostic test for womb cancer, known as the WID-qEC test. Developed by researchers at UCL’s Institute for Women’s Health in London (UK), the test aims to provide a quicker and less invasive alternative to the current diagnostic process. Womb cancer is the fourth most…

Andira Pharmaceuticals’ Breast Cancer Treatment Shows Promising Results

Andira Pharmaceuticals, a Canadian health science firm, has recently announced significant progress in the treatment of breast cancer with its pioneering formula, XOXO4. The company’s flagship oncology candidate, XOXO4, has demonstrated remarkable efficacy in regressing human breast cancer tumors. Conducted at the University of British Columbia, the study highlighted that XOXO4, a cannabinoid formula applied topically, outperformed all eight FDA-approved breast cancer-specific…

Recent Study Reveals Lasting Benefits of Eli Lily’s Verzenio in Early Stage Breast Cancer Treatment

A recent landmark study announced by Eli Lilly and Company has shown significant long-term benefits of Verzenio (abemaciclib) in treating high-risk early breast cancer (EBC). The findings, unveiled at the 2023 European Society for Medical Oncology (ESMO) Congress, are particularly significant for those at heightened risk of cancer recurrence. The study focused on hormone receptor-positive, HER2-negative, node-positive early breast cancer. Over five…